Journal of Applied Physiology AJP: Lung Cellular and Molecular Physiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

J Appl Physiol 82: 1593-1600, 1997;
8750-7587/97 $5.00
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ahlborg, G.
Right arrow Articles by Lundberg, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ahlborg, G.
Right arrow Articles by Lundberg, J. M.

Journal of Applied Physiology
Vol. 82, No. 5, pp. 1593-1600, May 1997
SYSTEMIC CIRCULATION AND FLUID BALANCE

Nitric oxide-endothelin-1 interaction in humans

Gunvor Ahlborg and Jan M. Lundberg

Department of Clinical Physiology, Huddinge University Hospital, S-141 86 Huddinge; and Department of Physiology and Division of Pharmacology, Karolinska Institute, S-171 77 Stockholm, Sweden

Received 10 April 1996; accepted in final form 24 January 1997.

Ahlborg, Gunvor, and Jan M. Lundberg. Nitric oxide-endothelin-1 interaction in humans. J. Appl. Physiol. 82(5): 1593-1600, 1997.---Healthy men received NG-monomethyl-L-arginine (L-NMMA) intravenously to study cardiovascular and metabolic effects of nitric oxide synthase blockade and whether this alters the response to endothelin-1 (ET-1) infusion. Controls only received ET-1. L-NMMA effects were that heart rate (17%), cardiac output (17%), and splanchnic and renal blood flow (both 33%) fell promptly (all P < 0.01). Mean arterial blood pressure (6%), and systemic (28%) and pulmonary (40%) vascular resistances increased (P < 0.05 to 0.001). Arterial ET-1 levels (21%) increased due to a pulmonary net ET-1 release (P < 0.05 to 0.01). Splanchnic glucose output (SGO) fell (26%, P < 0.01). Arterial insulin and glucagon were unchanged. Subsequent ET-1 infusion caused no change in mean arterial pressure, heart rate, or cardiac output, as found in the present controls, or in splanchnic and renal blood flow or splanchnic glucose output as previously found with ET-1 infusion (G. Ahlborg, E. Weitzberg, and J. M. Lundberg. J. Appl. Physiol. 79: 141-145, 1995). In conclusion, L-NMMA like ET-1, induces prolonged cardiovascular effects and suppresses SGO. L-NMMA causes pulmonary ET-1 release and blocks responses to ET-1 infusion. The results indicate that nitric oxide inhibits ET-1 production and thereby interacts with ET-1 regarding increase in vascular tone and reduction of SGO in humans.

NG-monomethyl-L-arginine and endothelin-1 infusion; cardiac output; splanchnic and renal blood flow; systemic and pulmonary vascular resistance; arterial levels and pulmonary release of endothelin-1; insulin and splanchnic glucose output

0161-7567/97 $5.00 Copyright © 1997 the American Physiological Society




This article has been cited by other articles:


Home page
 J. Physiol.Home page
D. Merkus, B. Houweling, V. J. de Beer, Z. Everon, and D. J. Duncker
Alterations in endothelial control of the pulmonary circulation in exercising swine with secondary pulmonary hypertension after myocardial infarction
J. Physiol., May 1, 2007; 580(3): 907 - 923.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
A. Lteif, P. Vaishnava, A. D. Baron, and K. J. Mather
Endothelin Limits Insulin Action in Obese/Insulin-Resistant Humans
Diabetes, March 1, 2007; 56(3): 728 - 734.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
K. J. Mather, A. Lteif, H. O. Steinberg, and A. D. Baron
Interactions Between Endothelin and Nitric Oxide in the Regulation of Vascular Tone in Obesity and Diabetes
Diabetes, August 1, 2004; 53(8): 2060 - 2066.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
F. D. Wagner, S. Buz, C. Knosalla, R. Hetzer, and B. Hocher
Modulation of Circulating Endothelin-1 and Big Endothelin by Nitric Oxide Inhalation Following Left Ventricular Assist Device Implantation
Circulation, September 9, 2003; 108(90101): II-278 - 284.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
N. Toda and T. Okamura
The Pharmacology of Nitric Oxide in the Peripheral Nervous System of Blood Vessels
Pharmacol. Rev., June 1, 2003; 55(2): 271 - 324.
[Abstract] [Full Text] [PDF]

Home page
 J. Appl. Physiol.Home page
G. Ahlborg and J. Lindstrom
Insulin sensitivity and big ET-1 conversion to ET-1 after ETA- or ETB-receptor blockade in humans
J Appl Physiol, December 1, 2002; 93(6): 2112 - 2121.
[Abstract] [Full Text] [PDF]

Home page
 J. Appl. Physiol.Home page
C. E. King-VanVlack, J. D. Mewburn, C. K. Chapler, and P. H. MacDonald
Endothelial modulation of skeletal muscle blood flow and VO2 during low- and high-intensity contractions
J Appl Physiol, February 1, 2002; 92(2): 461 - 468.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
T.-F. Chou, M.-S. Wu, C.-T. Chien, C.-C. Yu, and C.-F. Chen
Enhanced expression of nitric oxide synthase in the early stage after increased pulmonary blood flow in rats
Eur. J. Cardiothorac. Surg., February 1, 2002; 21(2): 331 - 336.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
A. Montanari, N. Carra, P. Perinotto, V. Iori, E. Fasoli, A. Biggi, and A. Novarini
Renal Hemodynamic Control by Endothelin and Nitric Oxide Under Angiotensin II Blockade in Man
Hypertension, February 1, 2002; 39(2): 715 - 720.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
A. Montanari, A. Biggi, N. Carra, E. Fasoli, M. Calzolari, F. Corsini, P. Perinotto, and A. Novarini
Endothelin-A Blockade Attenuates Systemic and Renal Hemodynamic Effects of L-NAME in Humans
Hypertension, January 1, 2000; 35(1): 518 - 523.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
P. J. M. Best, L. O. Lerman, J. C. Romero, D. Richardson, D. R. Holmes Jr, and A. Lerman
Coronary Endothelial Function Is Preserved With Chronic Endothelin Receptor Antagonism in Experimental Hypercholesterolemia In Vitro
Arterioscler. Thromb. Vasc. Biol., November 1, 1999; 19(11): 2769 - 2775.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
M Mundhenke, B Schwartzkopff, M Köstering, U Deska, R M Klein, and B E Strauer
Endogenous plasma endothelin concentrations and coronary circulation in patients with mild dilated cardiomyopathy
Heart, March 1, 1999; 81(3): 278 - 284.
[Abstract] [Full Text]

Home page
 CirculationHome page
J. A. M. Avontuur, F. Boomsma, A. H. van den Meiracker, F. H. de Jong, and H. A. Bruining
Endothelin-1 and Blood Pressure After Inhibition of Nitric Oxide Synthesis in Human Septic Shock
Circulation, January 19, 1999; 99(2): 271 - 275.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
A. Broere, A. H. Van Den Meiracker, F. Boomsma, F. H. M. Derkx, A. J. Man In'T Veld, and M. A. D. H. Schalekamp
Human renal and systemic hemodynamic, natriuretic, and neurohumoral responses to different doses of L-NAME
Am J Physiol Renal Physiol, December 1, 1998; 275(6): F870 - F877.
[Abstract] [Full Text] [PDF]

Home page
 J. Appl. Physiol.Home page
G. Ahlborg and J. M. Lundberg
Cyclooxygenase inhibition potentiates the renal vascular response to endothelin-1 in humans
J Appl Physiol, November 1, 1998; 85(5): 1661 - 1666.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online